Xxmbexxphaxxacexxicaxx IXX Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxmbexxphaxxacexxicaxx IXX Pharmaceutical Import Records from India — 4 Products, $7.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxmbexxphaxxacexxicaxx IXX — Pharmaceutical Importer Profile (2026) | 4 Products, $7.7M Trade | TransData Nexus

Xxmbexxphaxxacexxicaxx IXX

Pharmaceutical Importer · United States · Antivirals Focus · $7.7M Total Trade · DGFT Verified

Xxmbexxphaxxacexxicaxx IXX is a pharmaceutical importer based in United States with a total trade value of $7.7M across 4 products in 3 therapeutic categories. Based on 154 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxmbexxphaxxacexxicaxx IXX sources from 1 verified Indian supplier, with Hetero Labs Limited accounting for 100.0% of imports.

Xxmbexxphaxxacexxicaxx IXX — Import Portfolio & Supplier Network

Xxmbexxphaxxacexxicaxx IXX import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxmbexxphaxxacexxicaxx IXX?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Hetero Labs Limited	$13.1M	345	100.0%

Xxmbexxphaxxacexxicaxx IXX sources from 1 verified Indian supplier across 78 distinct formulations. The sourcing is highly concentrated — Hetero Labs Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Xxmbexxphaxxacexxicaxx IXX Import?

Formulation	Value	Ships
Montelukast sodium 10MG	$1.2M	25
Losartan potassium 100MG	$1.0M	22
Pantoprazole sodium 40MG	$895.2K	25
Valacyclovir 1000MG tablets (1x30's)	$750.0K	15
Rosuvastatin calcium 20MG	$611.2K	23
Rosuvastatin calcium 40MG	$534.8K	17
Rosuvastatin calcium 10MG	$516.9K	15
Valacyclovir 500MG	$450.0K	9
Losartan potassium 50MG	$450.0K	9
Valacyclovir 500MG tablets (1x30's)	$400.0K	8
Acyclovir 400MG tablets (1x100's)	$350.0K	7
Valacyclovir 1000MG tablets (1x90's)	$300.0K	6
Irbesartan 300MG	$300.0K	6
Valacyclovir 500MG tablets (1x90's)	$300.0K	6
Pantoprazole 40MG	$284.5K	7

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acyclovir	Antivirals	$3.2M	64	2.5%	4
2	Valacyclovir	Antivirals	$2.5M	49	2.6%	3
3	Montelukast	Respiratory	$1.9M	39	1.2%	6
4	Linezolid	Advanced Antibiotics	$100.0K	2	0.3%	7

Xxmbexxphaxxacexxicaxx IXX imports 4 pharmaceutical products across 3 categories into United States totaling $7.7M.

Xxmbexxphaxxacexxicaxx IXX — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxmbexxphaxxacexxicaxx IXX is a United States-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from India. The company operates as a buyer, sourcing a diverse range of pharmaceutical products to meet the demands of the U.S. market. While specific details about its headquarters and parent company are not publicly disclosed, Xxmbexxphaxxacexxicaxx IXX plays a significant role in the U.S. pharmaceutical distribution network by facilitating the importation of essential medications.

Over the period from 2022 to 2026, Xxmbexxphaxxacexxicaxx IXX has imported a total of $7.7 million worth of pharmaceutical products from India, encompassing 154 shipments. The company's portfolio includes four distinct products across three therapeutic categories, indicating a strategic approach to sourcing medications that address various health conditions prevalent in the United States.

2Distribution Network

Specific information regarding Xxmbexxphaxxacexxicaxx IXX's warehouse locations and logistics capabilities is not publicly available. However, given the scale of its operations, it is reasonable to infer that the company maintains a network of distribution centers strategically located to ensure efficient delivery of imported pharmaceutical products across the United States. The company's logistics operations are likely designed to comply with U.S. regulatory standards, ensuring timely and secure distribution of medications to meet market demand.

3Industry Role

Xxmbexxphaxxacexxicaxx IXX functions primarily as a pharmaceutical importer, sourcing finished drug products from Indian manufacturers for distribution within the United States. By importing a range of pharmaceutical formulations, the company contributes to the diversification and availability of medications in the U.S. market, particularly those that may not be readily available from domestic producers. This role is crucial in maintaining a robust pharmaceutical supply chain, ensuring that healthcare providers have access to a wide array of treatment options for their patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxmbexxphaxxacexxicaxx IXX

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxmbexxphaxxacexxicaxx IXX's sourcing strategy exhibits a high degree of concentration, with all imported products originating from a single supplier: HETERO LABS LIMITED. This exclusive sourcing arrangement, covering 100% of the company's imports, suggests a strategic partnership or long-term agreement between the two entities. While such concentration can lead to favorable terms and streamlined logistics, it also presents potential risks. Any disruptions in HETERO LABS LIMITED's production or supply chain could directly impact Xxmbexxphaxxacexxicaxx IXX's ability to meet market demand. Therefore, it is imperative for Xxmbexxphaxxacexxicaxx IXX to maintain a robust risk management strategy to mitigate potential supply chain disruptions.

2Supply Chain Resilience

The resilience of Xxmbexxphaxxacexxicaxx IXX's supply chain is closely tied to the stability and reliability of HETERO LABS LIMITED. Given the exclusive nature of their sourcing relationship, the company may face challenges in diversifying its supplier base. To enhance supply chain resilience, Xxmbexxphaxxacexxicaxx IXX could consider establishing relationships with additional suppliers, thereby reducing dependency on a single source. Additionally, evaluating alternative shipping routes and maintaining compliance with U.S. regulatory standards are essential steps to ensure uninterrupted access to critical pharmaceutical products.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for drug labeling, manufacturing practices, and importation procedures. For Indian pharmaceutical products to be imported into the U.S., they must comply with FDA regulations, including obtaining an FDA Establishment Identifier (FEI) number and ensuring that manufacturing facilities are registered with the FDA. Additionally, the FDA requires that drug products meet Good Manufacturing Practice (GMP) standards, which are detailed in 21 CFR Parts 210 and 211.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are governed by the FDA. Importers must ensure that their products are listed with the FDA and that manufacturing facilities are registered. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Xxmbexxphaxxacexxicaxx IXX must ensure that their manufacturing facilities hold valid GMP certifications recognized by the FDA. Additionally, they must obtain an FDA Establishment Identifier (FEI) number and comply with all FDA regulations pertaining to drug importation.

Xxmbexxphaxxacexxicaxx IXX — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxmbexxphaxxacexxicaxx IXX's product strategy focuses on importing pharmaceutical formulations in the antiviral, respiratory, and advanced antibiotic categories. The company's top five imported products include Acyclovir, Valacyclovir, Montelukast, and Linezolid, which are commonly used to treat conditions such as herpes simplex virus infections, influenza, asthma, and bacterial infections, respectively. The demand for these products in the U.S. market is driven by the prevalence of these health conditions and the need for effective treatments. By sourcing these medications from India, Xxmbexxphaxxacexxicaxx IXX contributes to the availability and affordability of essential drugs in the U.S. market.

2Sourcing Profile

Xxmbexxphaxxacexxicaxx IXX's sourcing strategy is centered on importing generic drug formulations from India, focusing on finished pharmaceutical products rather than active pharmaceutical ingredients (APIs). This approach allows the company to offer a diverse range of medications to the U.S. market, catering to various therapeutic needs. India's well-established pharmaceutical manufacturing industry, characterized by its adherence to international quality standards and cost-effective production capabilities, makes it an attractive sourcing destination for Xxmbexxphaxxacexxicaxx IXX.

3Market Positioning

Seller's Guide — How to Become a Supplier to Xxmbexxphaxxacexxicaxx IXX

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the U.S. market through partnerships with importers like Xxmbexxphaxxacexxicaxx IXX. To capitalize on this opportunity, Indian exporters should focus on ensuring that their products meet FDA standards, including obtaining recognized GMP certifications and complying with labeling and serialization requirements. Additionally, establishing a reputation for reliability and quality can enhance the attractiveness of their offerings to U.S. importers. By addressing these factors, Indian suppliers can position themselves as valuable partners in the U.S. pharmaceutical supply chain.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Xxmbexxphaxxacexxicaxx IXX

What products does Xxmbexxphaxxacexxicaxx IXX import from India?

Xxmbexxphaxxacexxicaxx IXX imports 4 pharmaceutical products across 3 categories. Top imports: Acyclovir ($3.2M), Valacyclovir ($2.5M), Montelukast ($1.9M), Linezolid ($100.0K).

Who supplies pharmaceuticals to Xxmbexxphaxxacexxicaxx IXX from India?

Xxmbexxphaxxacexxicaxx IXX sources from 1 verified Indian suppliers. The primary supplier is Hetero Labs Limited (100.0% of imports, $13.1M).

What is Xxmbexxphaxxacexxicaxx IXX's total pharmaceutical import value?

Xxmbexxphaxxacexxicaxx IXX's total pharmaceutical import value from India is $7.7M, based on 154 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxmbexxphaxxacexxicaxx IXX focus on?

Xxmbexxphaxxacexxicaxx IXX imports across 3 categories. The largest: Antivirals (73.4%), Respiratory (25.3%), Advanced Antibiotics (1.3%).

Get Full Xxmbexxphaxxacexxicaxx IXX Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.